Glioblastoma, Prostate cancer, Squamous Cell Carcinoma of the Head and Neck | Access and Reimbursement | US | 2016

The success of an anticancer therapy is not only dependent on the outcome of its pivotal trial, but also on that trial’s design, which is examined by the regulatory bodies, payers, and prescribers. In our analysis, we assess the influence of trial design on treatment and reimbursement decisions regarding current and emerging therapies for glioblastoma, prostate cancer, and squamous cell carcinoma of the head and neck (SCCHN). In addition, we explore payers’ and prescribers’ cost-sensitivity and preference for trial design features, such as primary end points, comparators, and enrollment size.

Login to access report